CTLA4 and malignant colon neoplasm: According to the latest NCCN colon cancer guidelines (2021 V2), PD-1 inhibitors or PD-1 inhibitors combined with low-dose CTLA4 inhibitors can be used as first-line treatments for dMMR/MSI-H metastatic colon cancer [30].